Puerto Rico Despite being a small island in the Caribbean, measuring just 100 by 35 miles, Puerto Rico has long punched above its weight as an industrial powerhouse. Already a leading producer of everything from blockbuster medicines to high-tech medical devices, how has it got to this point and what comes next?…
Puerto Rico Across over 50 interviews with Puerto Rican government and industry stakeholders, energy supply was continuously identified as the main barrier to growth. Puerto Rico’s ageing, centralised, and fossil fuel–dependent power system remains vulnerable to disruption from hurricanes and other natural events. However, new investments in renewables, battery storage, and decentralised…
Europe As China and the US attract an increasing share of commercial clinical trials, Europe is fighting to reclaim its spot as a global research leader. While Europe has world-class hospitals and experienced regulators, it has struggled with a complicated and fragmented approval system that has pushed trial sponsors elsewhere. To…
Puerto Rico Carlos Ceinos, President & Co-Founder of Principia, leads a Puerto Rico-based consulting firm focused on automation, MES, project management, and validation for the biopharmaceutical industry. Since 2019, the company has doubled in size and expanded into the U.S. and Canada, driven by expertise, trust, and flexibility. Now entering a management…
Europe To address the European Union’s drop in global share of clinical trials over the past decade, stakeholders are working together to deliver a dynamic, agile, responsive EU clinical trials environment. As Katarina Nedog of the European Federation of Pharmaceutical Industries and Associations (EFPIA) points out in the March 2025 edition…
Europe Will a new ‘Critical Medicines Act’ go far enough to ensure Europe’s resilience to future health crises? A Continent at Risk The COVID-19 pandemic exposed serious vulnerabilities in the European medicine supply chain. EU countries suddenly found themselves competing for limited supplies of sedatives and antibiotics for ICU care,…
Belgium Belgium, one of Europe’s most important countries for biopharmaceutical production and R&D, assumed presidency of the Council of the European Union on the first of January. As part of its Presidency Programme, Belgium has highlighted health as one of its 14 focus areas, with the hope of strengthening the three…
Europe The European Federation of Pharmaceutical Industries and Associations (EFPIA) has elected a new president and vice presidents who have set out a key priority for their term: a series of amendments to the proposed European Commission (EC) pharmaceutical legislation reform, which the organisation has warned will further accelerate the loss…
Europe As part of the EU’s Pharmaceutical Strategy for Europe, the European Commission has come out with a set of proposals to revise EU pharmaceutical legislation. The reforms, which aim to make medicines more available and accessible across Europe by reducing regulatory exclusivity, speeding up review processes and reinforcing supply chains…
Europe In Europe, patient access to Orphan Medicinal Products (OMP) for the treatment of rare diseases remains inequitable. With the common goal of ensuring broader and faster access to OMPs across Europe, EURORDIS and EFPIA have joined forces to propose a series of solutions. According to a 2020 study, fragmentation of…
Global The COVID-19 pandemic brought the issue of access to medicines to the forefront. Not only did supply chain disruptions lead to initiatives designed to make sure essential medicines reach patients, but the pandemic also served to underline a number of pre-existing access inequalities. Several of PharmaBoardroom’s recent interviewees have discussed…
Europe Nathalie Moll, Director General of the European Federation of Pharmaceutical Industries and Associations (EFPIA) shares her views on the pharma industry’s response to COVID-19 and Europe’s preparedness for future health crises. She also discusses the reach and ambition of the Pharma Strategy and addresses the issues around equitable access. …
See our Cookie Privacy Policy Here